CSL will outlay $1.5bn over the next five years in the US to grow its footprint of plasma therapy production, the latest pharma company to pour money into the country amid tariff threats.

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...

Want a feel-good side gig that requires no work, no skill and no experience? Consider plasma donation through CSL Plasma. It’s a lot like giving blood, but you get paid — sometimes generously. CSL ...